ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



AXLÀÒ°±ËἤøµÄÌ«¹ý±í´ï»ò¼¤»îÓëÑ×Ö¢µÄ±¬·¢¡¢Éú³¤ÒÔ¼°Ö×ÁöµÄÇÖÏ®¡¢×ªÒƵÈÀú³ÌÇ×½üÏà¹Ø¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬Õë¶ÔAXLµÄÑо¿Ö±µ½½üÄêÀ´²ÅÊܵ½ÆÕ±éµÄ¹Ø×¢¡£¡£¡£¡£¡£2013ÄêÊ׸öAXLÒÖÖÆ¼Á½øÈëÁÙ´²ÊÔÑ飬£¬£¬£¬³ÉΪAXL×÷Ϊ¿¹°©°ÐµãµÄÒ»¸öÖ÷ÒªÀï³Ì±®¡£¡£¡£¡£¡£Istvan SzabadkaiµÈÈË[1]×î½üÌá³öÁËÒ»¸öеÄС·Ö×Ó»¯ºÏÎï21f£¬£¬£¬£¬ÐÎòÁËÆä½á¹¹¡¢ºÏ³ÉºÍÉúÎï»îÐÔ£¬£¬£¬£¬²¢Ö¤ÊµÊÇÒ»ÖÖÑ¡ÔñÐÔµÄAXLÀÒ°±ËἤøÒÖÖÆ¼Á¡£¡£¡£¡£¡£ÔÚδÊӲ쵽¶¾ÐÔµÄÇéÐÎÏ£¬£¬£¬£¬ÔÚÈËÀàÈéÏÙ°©ÒìÖÖÒÆÖ²Ä£×ÓÖУ¬£¬£¬£¬Ê¹ÓÃ21fºó¾Ö²¿Ö×ÁöÕϰÉú³¤µÄ¼¸Âʵִï40%£¬£¬£¬£¬ÕâÅú×¢21f¾ßÓгÉÒ©µÄ¿ÉÄÜÐÔ£¬£¬£¬£¬ÖµµÃ½øÒ»²½µÄÏêϸÑо¿ºÍ̽Ë÷¡£¡£¡£¡£¡£

AXL°Ðµã¹éÄÉ×ÛºÏ
ÊÜÌåÀÒ°±Ëἤø(RTKs)ÊÇÅþÁ¬Ï¸°ûÍâºÍϸ°ûÄÚÇéÐεĿçĤÂѰס£¡£¡£¡£¡£×÷ΪÐźÅתµ¼µÄµ÷½âÕߣ¬£¬£¬£¬ÆäÔÚÕý³£µÄϸ°ûÀú³ÌÖÐÊÎÑÝÁËÖ÷ÒªµÄ½ÇÉ«£¬£¬£¬£¬°üÀ¨·Ö½â¡¢Õ³¸½¡¢Ç¨áã¡¢µòÍö¡¢´úл¡£¡£¡£¡£¡£²¸È鶯ÎïµÄÊÜÌåÀÒ°±ËἤøÖÐÓÐÒ»¸öÑǿƳÆÎªTAM¼Ò×壬£¬£¬£¬°üÀ¨AXL¡¢MERºÍTYRO-3¡£¡£¡£¡£¡£AXL¼¤Ã¸µÄ¹ý±í´ï×î³õÊÇÔÚÂýÐÔÁ£Ï¸°û°×Ѫ²¡ºÍÂýÐÔ¹ÇËèÔöÉúÖ¢Öз¢Ã÷µÄ¡£¡£¡£¡£¡£Ëæºó£¬£¬£¬£¬PaccezµÈÈË·¢Ã÷ÔÚÈéÏÙ°©¡¢·Î°©¡¢Ç°ÏßÏÙ°©¡¢½á³¦°©¡¢Ê³¹Ü°©¡¢¸Î°©µÈ¶àÖÖ°©Ö¢ÖÐÒ²±£´æAXL¼¤Ã¸¹ý±í´ï¡£¡£¡£¡£¡£
AXLÊÜÌåÀÒ°±ËἤøÊÇÓɰûÍâÇø¡¢¿çÄ¤ÇøºÍ°ûÄÚÇø×é³É£¬£¬£¬£¬ÊôÓÚ¢ñÐÍ¿çĤµ¥Á´¡£¡£¡£¡£¡£Æä°ûÍâÅäÌåÁ¬ÏµÇøÓòÓÉÁ½¸öÃâÒßÇòÂѰ׵ĽṹÓòºÍÁ½¸öÏËάÂѰ׵ÄÖØ¸´ÐòÁÐÏàÁ¬¶ø³É£»£»£»°ûÄÚ¶ÎÊÇÀÒ°±ËáÂѰ׼¤Ã¸µÄ´ß»¯²¿Î»£¬£¬£¬£¬¾ßÓÐ×ÔÉíÁ×ËữµÄÌØµã¡£¡£¡£¡£¡£°ûÍâ¶ÎÔòͨ¹ýÒ»¸öaÂÝÐý¿çĤ½á¹¹Óë°ûÄÚµÄÀÒ°±ËἤøÏàÁ¬¡£¡£¡£¡£¡£

AXL¿ÉÒÔ±»¶àÖÖ»úÖÆ¼¤»î£¬£¬£¬£¬»î»¯·½·¨ÏêϸÓÐ:(1)AXLÓëGAS6ÅäÌåÒÀÀµÐԻ;(2) AXLµÄÅäÌå×ÔÁ¦»î»¯;(3)·ÇTAM¼Ò×åÂѰ׶ÔAXLµÄÒìÔ´¼¤»î;(4) MER»òTYRO3¶ÔAXLµÄÒìÔ´¼¤»î;(5) AXLµÄ°ûÍâÅäÌå×ÔÁ¦»î»¯¡£¡£¡£¡£¡£×î³£¼ûµÄÊÇÅäÌåÒÀÀµÐÔ¼¤»î£¬£¬£¬£¬ÆäÖÐAXLÓëGAS6Á¬Ïµ£¬£¬£¬£¬ÐγÉÓÉÁ½¸öAXL·Ö×ÓÓëÁ½¸öGAS6·Ö×ÓÁ¬ÏµµÄ¶þ¾ÛÌ帴ºÏÎï¡£¡£¡£¡£¡£ÆäËûµÄ¼¤»î»úÖÆÒ²¿ÉÄܻᱬ·¢£¬£¬£¬£¬Èçµ±AXL±»Ì«¹ý±í´ï»òÔÚÑõ»¯Ó¦¼¤Ï£¬£¬£¬£¬ÍùÍù»á±¬·¢ÅäÌå×ÔÁ¦¼¤»î[2]£»£»£»ÒÔ¼°ÔÚBϸ°ûÂýÐÔÁܰÍϸ°û°×Ѫ²¡Öз¢Ã÷AXLºÍTYRO3µÄ¶þ¾Û»¯[3]¡£¡£¡£¡£¡£

AXLÒÖÖÆ¼ÁµÄÑо¿ÏÖ×´
ÒÑÓÐÑо¿·¢Ã÷£¬£¬£¬£¬TAMÐźÅתµ¼ÔÚµòÍöϸ°ûµÄɨ³ý¡¢¹ÌÓÐÃâÒßÒÔ¼°Ñ×Ö¢µ÷Àí·´Ó¦ÖÐÆð×ÅÖ÷ÒªµÄ×÷Óᣡ£¡£¡£¡£TAMµÄÐźÅȱÏÝ¿ÉÒÔµ¼ÖµòÍöϸ°ûɨ³ýÕϰÒÔ¼°¹ÌÓÐÃâÒß·´Ó¦ÖÐÑ×Ö¢µÄÎÞÏÞÖÆ¼¶Áª·Å´ó¡£¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬Í¨¹ýÒÖÖÆTAMÐźÅתµ¼£¬£¬£¬£¬¿ÉÒÔµÖ´ïÖÎÁư©Ö¢»ººÍ½âÃâÒßÒÖÖÆµÄЧ¹û£¬£¬£¬£¬²¢ÄÜÖÎÁÆÍíÆÚ°ÜѪÐÔÐݿˡ£¡£¡£¡£¡£
åÇÀ´µÄÑо¿ÏÔʾ£¬£¬£¬£¬¼¤»îµÄAXL»á×ÊÖú°©Ï¸°ûÉú³¤³ö¶Ô¶òÂåÌæÄáµÄÄÍÒ©ÐÔ£¬£¬£¬£¬¶øÔÚϸ°ûÖÐÒÖÖÆAXL»îÐÔ£¬£¬£¬£¬ÔòÄָܻ´Ï¸°û¶Ô¶òÂåÌæÄáµÄÃô¸ÐÐÔ¡£¡£¡£¡£¡£Èô½«AXLÒÖÖÆ¼ÁºÍ¶òÂåÌæÄá×éºÏʹÓÃÔòÄܹ»ÊµÏÖÓÅÊÆ»¥²¹¡£¡£¡£¡£¡£Ò»·½Ã棬£¬£¬£¬¼¤Ã¸ÒÖÖÆ¼ÁÄܹ»¿ìËÙÒÖÖÆÖ×Áöϸ°û£¬£¬£¬£¬²¢ÔöÇ¿Íç¹ÌÖ×Áö¶Ô¶òÂåÌæÄáµÄÃô¸ÐÐÔ£»£»£»ÁíÒ»·½Ãæ¶òÂåÌæÄáÄܹ»×ÊÖú¼¤Ã¸ÒÖÖÆ¼Áʩչ³¤ÆÚµÄ¿¹Ö×Áö×÷Óᣡ£¡£¡£¡£±ðµÄ¼¤Ã¸ÒÖÖÆ¼Á»¹Äܹ»ÐÖú»î»¯Tϸ°ûÀ´É¨³ýÖ×Áöϸ°û¡£¡£¡£¡£¡£BerGenBio¾Í»ùÓÚÉÏÊö¿´·¨£¬£¬£¬£¬×¨×¢¿ª·¢AXL¼¤Ã¸ÒÖÖÆ¼Á£¬£¬£¬£¬ÊÔͼ½«ÆäÉú³¤³É°©Ö¢ÖÎÁÆÖÐÁªÊÊÓÃÒ©µÄ»ùʯ֮һ¡£¡£¡£¡£¡£ÏÂͼΪÒѱ¨µÀµÄ¶ÔAXLÓлîÐÔµÄС·Ö×ÓÀÒ°±ËἤøÒÖÖÆ¼Á¡£¡£¡£¡£¡£

È»¶ø£¬£¬£¬£¬ÉÏÊöС·Ö×Ó¼¤Ã¸ÒÖÖÆ¼ÁµÄÆðʼĿµÄ°Ðµã²¢²»ÊÇAXL£¬£¬£¬£¬µÚÒ»¸öÕë¶ÔAXL¼¤Ã¸µÄÑ¡ÔñÐÔÒÖÖÆ¼ÁÊÇ»¯ºÏÎïR428£¨BGB-324£©(7) [4]¡£¡£¡£¡£¡£Æä×÷ÓûúÖÆÊÇÒÖÖÆAXLµÄÁ×Ëữ£¬£¬£¬£¬Í»ÆÆÄ¤ÉÏAXL¼¤Ã¸µÄÎÈ̬µ÷¿Ø£¬£¬£¬£¬´Ó¶øÏµ÷AXLĤÉϵıí´ïÁ¿¡£¡£¡£¡£¡£BGB-324ÊÇBerGenBio¹«Ë¾Ñз¢µÄͬÀàÊ×´´¡¢¸ßÑ¡ÔñÐÔ¡¢ÉúÎï¿ÉÓõĿڷþAXLС·Ö×ÓÒÖÖÆ¼Á¡£¡£¡£¡£¡£

AXLÔÚ²î±ðʵÌåºÍ°©Ö¢µÄÉúÑÄ¡¢À©É¢ºÍÄÍÒ©»úÖÆÖеÄÍ»³ö×÷Ó㬣¬£¬£¬¶¼Åú×¢AXLÒÖÖÆ×÷ΪһÖÖ¿¹°©Ò©Î£¬£¬£¬ÌØÊâÊÇÕë¶ÔÍíÆÚ¼²²¡£¬£¬£¬£¬ÖµµÃÆÚÐí¡£¡£¡£¡£¡£ÏÖÔÚÕë¶ÔAXLµÄÖÖÖÖºòѡҩÎïÕýÔÚÁÙ´²Ñо¿ÖУ¬£¬£¬£¬Ô¤¼Æ»áÓиü¶àµÄÒ©ÎïÎÊÊÀ£¬£¬£¬£¬¿ÉÒÔΪ°©Ö¢»¼ÕßÌṩеÄÖÎÁƼƻ®¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1, Istva??ri,?? AxelChoidas, Axel Ullrich and La?szlo??r?6292.
2, Heiring, C. Dahlback, B. Muller, Y. A.Ligand recognition and homophilic interactions in Tyro3: structural insightsinto the Axl/Tyro3 receptor tyrosine kinase family J. Biol. Chem. 2004, 279,6952-6958.
3, Sinha, S. Boysen, J. Nelson, M.;Secreto, C. Warner, S. L. Bearss, D. J. Lesnick, C. Shanafelt, T. D. Kay,N. E. Ghosh, A. K. Targeted Axl inhibition primes Chronic Lymphocytic LeukemiaB cells to apoptosis and shows synergistic/additive effects in combination withBTK inhibitors Clin. Cancer Res. 2015, 21, 2115-2126.
4, Holland, S. J. Pan,A. Franci, C. Hu, Y. Chang, B. Li, W. Duan, M. Torneros, A. Yu, J. Heckrodt, T. J. Zhang, J. Ding, P. Apatira, A.; Chua, J. Brandt, R. Pine,P. Goff, D. Singh, R. Payan,D. G. Hitoshi, Y. R428,a selective small molecule inhibitor of AXL kinase, blocks tumor spread andprolongs survival in models of metastatic breast cancer. Cancer Res. 2010, 70,1544?1554.
Ïà¹ØÐÂÎÅ